<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805307</url>
  </required_header>
  <id_info>
    <org_study_id>KYM901</org_study_id>
    <nct_id>NCT04805307</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901</brief_title>
  <official_title>An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to&#xD;
      evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.&#xD;
&#xD;
      The dose escalation part (Part A) will determine the MTD of CMG901 in subjects with relapsed&#xD;
      and/or refractory advanced solid tumor for which there is no available standard therapy&#xD;
      likely to confer clinical benefit, or the subject is not a candidate for such available&#xD;
      therapy based on a modified 3+3 dose escalation design (an accelerated dose titration design&#xD;
      followed by traditional 3+3 dose escalation design).&#xD;
&#xD;
      The dose expansion part (Part B) will evaluate the preliminary anti-tumor activity and safety&#xD;
      of CMG901 in subjects with Claudin 18.2 positive gastric cancer (GC), gastroesophageal&#xD;
      junction (GEJ) cancer, and pancreatic cancer who have relapsed and/or are refractory to&#xD;
      approved therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A, Dose Escalation: Modified 3+3 dose escalation design: an accelerated dose titration design followed by traditional 3+3 dose escalation design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants with a Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 21 days after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</measure>
    <time_frame>Up to 30 days after the last dose of CMG901 or until the start of subsequent anticancer therapy, if earlier</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Objective Response Rate, Assessed According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: AUC to the last quantifiable concentration [AUC(0-last)], over the dosing interval [AUC(0-tau)], extrapolated to infinity [AUC(0-inf), time to Cmax (tmax), apparent half-life (t1/2), systemic clearance (CL).</measure>
    <time_frame>21 days after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: AUC(0-last), AUC(0-tau), Cmax, tmax, t1/2, systemic clearance (CL), volume of distribution (Vz, Vss), minimum concentration (Cmin), Ctrough, accumulation ratios for Cmax and AUC(0-tau) for multiple doses</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: Incidence of anti-CMG901</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: Disease Control Rate, Assessed According to RECIST v1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: Duration of Response, Assessed According to RECIST v1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: Progression Free Survival, Assessed According to RECIST v1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Claudin 18.2 expression by retrospective testing in tumor specimens by immunohistochemistry</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: ORR, Assessed according to RECIST 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; Part B: Overall Survival</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence, severity, and outcome of TEAEs and SAEs based on NCI CTCAE version 5.0</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part A, Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Dose expansion _GC_ MTD level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.&#xD;
The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Dose expansion _PC_ MTD level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.&#xD;
The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Dose expansion _GC_ MTD-1 level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.&#xD;
The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Dose expansion _PC_ MTD-1 level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.&#xD;
The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMG901</intervention_name>
    <description>CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.</description>
    <arm_group_label>Part A, Dose escalation</arm_group_label>
    <arm_group_label>Part B, Dose expansion _GC_ MTD level</arm_group_label>
    <arm_group_label>Part B, Dose expansion _GC_ MTD-1 level</arm_group_label>
    <arm_group_label>Part B, Dose expansion _PC_ MTD level</arm_group_label>
    <arm_group_label>Part B, Dose expansion _PC_ MTD-1 level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Part A: Patient must have histologically or cytologically confirmed advanced and/or&#xD;
             metastatic solid tumor malignancies for which standard treatment do not exist, are no&#xD;
             longer effective, or are not acceptable to the patient.&#xD;
&#xD;
          -  Part A: Must provide archival tumor tissue specimen or agree to undergo a fresh biopsy&#xD;
             if archival specimen is unavailable for retrospective Claudin 18.2 testing prior to&#xD;
             enrollment; Claudin 18.2 expression is not required for enrollment.&#xD;
&#xD;
          -  Part A: Measurable or evaluable disease per RECIST v 1.1.&#xD;
&#xD;
          -  Part B: Histologically-confirmed, advanced unresectable or metastatic GC, GEJ&#xD;
             adenocarcinoma, or pancreatic cancer which have relapsed and/or are refractory to&#xD;
             approved therapies.&#xD;
&#xD;
          -  Part B: CLDN18.2-positive tumor sample assessed by central testing. New biopsies and&#xD;
             archival bio-samples are allowed. If archival tissue samples from several points of&#xD;
             time are available, the most recent one is preferred.&#xD;
&#xD;
          -  Part B: Measurable disease per RECIST v 1.1.&#xD;
&#xD;
          -  Women of childbearing potential and male subjects must agree to remain abstinent or&#xD;
             use contraceptive methods as defined by the protocol.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status 0-1.&#xD;
&#xD;
          -  Side effects of any prior therapy or procedures for any medical condition has&#xD;
             recovered to NCI-CTCAE v.5.0 Grade ≤ 1 or stable status by investigator.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Received: chemotherapy or any investigational anti-tumor agents within 28 days of the&#xD;
             start of CMG901 treatment; molecularly-targeted agents, immunoconjugate, or antibody&#xD;
             drug conjugate within 28 days or or 5 half-lives (whichever is shorter) of the start&#xD;
             of CMG901 treatment; major surgery within 28 days of the start of CMG901 treatment;&#xD;
             radiotherapy within 21 days of the start of CMG901 treatment; potent cytochrome P450&#xD;
             3A4 (CYP3A4) inhibitors within 14 days or or 5 half-lives (whichever is longer) of the&#xD;
             start of CMG901 treatment.&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or requiring another form of chronic immunosuppressive&#xD;
             therapy. Or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg&#xD;
             daily of prednisone or equivalent) within 7 days prior to the first dose.&#xD;
&#xD;
          -  History of severe hypersensitivity to any component or excipient of CMG901.&#xD;
&#xD;
          -  Ongoing or active infection assessed by investigator.&#xD;
&#xD;
          -  Any severe cardiac dysfunction including left ventricular ejection fraction &lt;50%,&#xD;
             congestive heart failure ≥Grade 2 (New York Heart Association), QTc &gt;480 msec, history&#xD;
             of acute myocardial infarction, angina pectoris, uncontrolled arrhythmia, acute&#xD;
             coronary syndromes, stent placement, stroke, or transient ischemic attack within 6&#xD;
             months of enrollment.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Subjects with uncontrolled ascites, pleural effusion, or pericardial effusion by&#xD;
             investigator.&#xD;
&#xD;
          -  Preexisting sensory and/or motor neuropathy Grade ≥2.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus or diabetic neuropathy within 3 months of the first&#xD;
             dose of CMG901.&#xD;
&#xD;
          -  Known infection with HIV, or HIV positive; Known active hepatitis B, or HBsAg positive&#xD;
             with HBV-DNA positive, or anti-HBc positive with HBV-DNA positive; Known active&#xD;
             hepatitis C, or anti-HCV antibody positive with HCV-RNA positive.&#xD;
&#xD;
          -  Any severe and/or uncontrolled systemic disease or other conditions that in the&#xD;
             opinion of the Investigator make the subject unsuitable for participation in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qian Jia</last_name>
    <phone>028-88610620</phone>
    <email>qianjia@keymedbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Liu</last_name>
    <phone>028-88610620</phone>
    <email>qianjia@keymedbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center (SYSUCC)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Dr.</last_name>
      <phone>020-87343468</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Ruihua Xu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suxia Luo</last_name>
    </contact>
    <investigator>
      <last_name>Suxia Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Wang</last_name>
    </contact>
    <investigator>
      <last_name>Yongsheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

